| Former Name: | Alder Biopharmaceuticals |
| Type: | Subsidiary |
| Hq Location City: | Bothell, Washington |
| Hq Location Country: | U.S. |
| Parent: | Lundbeck |
| Website: | https://www.lundbeck.com/us/about-us/lundbeck-in-the-us |
Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.
In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise .[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]
As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4] [5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]